Ruishi Technology has successfully concluded its A2 round of financing, securing tens of millions of yuan. These funds will be allocated towards the advancement of core product research and development, the registration and declaration of Class III medical devices, as well as market expansion efforts. The company is a pioneer in AI optical eye-brain neural regulation technology and has introduced a range of far-image products, ushering in a new era of digitized and personalized myopia management. Clinical trials have demonstrated that Ruishi's products exhibit remarkable efficacy in slowing down the progression of myopia, with some test subjects experiencing a reduction in axial length by up to 50%, and even cases of mild myopia being reversed. Furthermore, Ruishi Technology spearheaded the issuance of China's first far-image technology group standard, setting the benchmark for industry standardization. Currently, its products are available in over 400 cities nationwide and are utilized in more than 600 professional institutions.